Seres Therapeutics Inc (MCRB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.090.00%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · MCRB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -37.8% |
| Our one-year growth estimate | diamond | -83.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 45.3 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
MCRB — CFO transition
Dated 2026-10-26
CFO — Marella Thorell: The resignation of the Chief Financial Officer is a significant loss of a senior executive, and no immediate successor is named in the filing.
Why it matters: Seres had $15.6 million in cash at June 30 and said funds would last through Q1 2027. New capital could give its trials more time.
Watch forA filing or earnings release shows cash or new funding that extends the stated runway beyond Q1 2027.
Also watch forSeres reports a shorter runway than Q1 2027, or says planned work is paused for lack of cash.
Why it matters: Seres ended one lease early and cut space under another lease. Lower cash costs could help preserve funds for its programs.
Supportive ifQ3 results show lower facility costs. The company confirms the Sidney Street lease ends by December 31, 2026.
Worry ifQ3 results show new or higher facility costs, or Seres reports the lease exit did not reduce planned cash costs.
Why it matters: The CFO left, and no successor was named in the event summary. A named successor would restore a clear finance lead as cash needs remain high.
Worry ifA filing names a new CFO within the next two quarters.
Less concerning ifTwo quarters pass with no named CFO, or Seres reports another senior finance staff departure.
Why it matters: SER-155 is ready for Phase 2 in allo-HCT, but Seres says it needs funding first. A funded trial would restart this program.
Supportive ifSeres announces a financing or partner deal and gives a start date for the SER-155 allo-HCT Phase 2 trial.
Worry ifSeres reports no funding or trial start plan, while its cash runway remains near Q1 2027.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$333 on $10,000 · ±3.3% | How much price usually moves either way. |
| Bad day | $802 loss on $10,000 · 8.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,382 loss on $10,000 · 93.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The small MSK study showed day-15 responses in 12 of 15 patients. A trial plan or partner would help move this result forward.
Supportive ifSeres names a Phase 2 start window or signs a partner deal that funds SER-155 work in irEC.
Worry ifSeres reports no partner or funded trial plan, or delays the next step beyond its stated plan.